{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:58:40Z","timestamp":1774522720313,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-COVID condition (PCC) encompasses a heterogeneous spectrum of pathological responses to SARS-CoV-2 infection, with unknown individual predispositions. No evidence-based, curative treatments are available. Many patients therefore resort to off-label use of medications originally developed for other indications. However, the efficacy and safety of repurposed drugs in the context of PCC are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RECLAIM is a phase III, randomised, controlled, adaptive platform trial. The trial population consists of adult patients who have had persistent PCC symptoms, including fatigue and\/or post-exertional malaise, 12 or more weeks after the onset of a SARS-CoV-2 infection. Randomisation occurs within trial domains. A trial domain consists of one or multiple investigational products (IPs), each to be compared to one usual care arm, or one or multiple IPs, each to be compared to a matching placebo. Within each trial domain, patients can be enrolled if they are eligible for at least one IP and its control. They are randomised with equal probability to each arm for which they are eligible. Trial product use (if applicable) starts as soon as possible after randomisation for a default duration of 12 weeks. Study procedures are implemented remotely, using video consultations, eConsenting, trial product delivery to participants\u2019 homes (if applicable), and online questionnaires at baseline, day 1, and weeks 2, 4, 6, 8, 10, 12, and 24. The primary outcome is health-related quality of life at week 12, assessed by Patient-Reported Outcomes Measurement Information System Profile29 (PROMIS-29) physical health summary scores, and is analysed with a Bayesian analysis of covariance model with adjustment for the baseline value. Secondary outcomes include week 12 PROMIS-29 mental health summary scores and topic domain scores; specific PCC symptoms using other patient-reported outcome measures, safety, and tolerability; and durability of treatment responses at week 24. Participants are allowed to participate in only one trial domain at a time, but can be rerandomised into a different trial domain after completing week 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>RECLAIM commenced in February 2025 with an open-label domain including two IP arms (metformin and colchicine) and one usual care control arm. A second placebo-controlled domain, comparing minocycline to a matching placebo, was initiated in February\u00a02026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      European Clinical Trials Information System (CTIS) EUCT number\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&amp;EUCT=2024-511580-28-02\" ext-link-type=\"uri\">2024-511580-28-02<\/jats:ext-link>\n                      . Registered on 9 October 2024. ClinicalTrials.gov identifier\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT07280572?cond=Post-COVID-19%20Syndrome&amp;term=RECLAIM&amp;rank=1\" ext-link-type=\"uri\">NCT07280572<\/jats:ext-link>\n                      . Registered on 11 December 2025.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09570-1","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:04:43Z","timestamp":1771488283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The RECLAIM adaptive platform trial for the evaluation of treatments for post-COVID condition in the Netherlands: core protocol"],"prefix":"10.1186","volume":"27","author":[{"given":"Janneke H. H. M.","family":"van de Wijgert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M. H.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd D.","family":"Swarthout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wietske J. T.","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"van Rosmalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien R.","family":"Leffelaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arief","family":"Lalmohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Loch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cees C.","family":"van den Wijngaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Prat-Aymerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost J.","family":"Schotsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline D.","family":"Verheijen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna G.","family":"van der Bom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"9570_CR1","doi-asserted-by":"crossref","unstructured":"Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22:e102\u2013e107.","DOI":"10.1016\/S1473-3099(21)00703-9"},{"issue":"10453","key":"9570_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0140-6736(24)01136-X","volume":"404","author":"T Greenhalgh","year":"2024","unstructured":"Greenhalgh T, Sivan M, Perlowski A, Nikolich J\u017d. Long COVID: a clinical update. Lancet. 2024;404(10453):707\u201324.","journal-title":"Lancet"},{"key":"9570_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0950268823001139","volume":"151","author":"I Gerritzen","year":"2023","unstructured":"Gerritzen I, Brus IM, Spronk I, Biere-Rafi S, Polinder S, Haagsma JA. Identification of post-COVID-19 condition phenotypes, and differences in health-related quality of life and healthcare use: a cluster analysis. Epidemiol Infect. 2023;151:1\u201310.","journal-title":"Epidemiol Infect"},{"key":"9570_CR4","doi-asserted-by":"crossref","unstructured":"Gentilotti E, G\u00f3rska A, Tami A, Gusinow R, Mirandola M, Rodr\u00edguez Ba\u00f1o J, et al; ORCHESTRA Study Group. Clinical phenotypes and quality of life to define post-COVID-19 syndrome: a cluster analysis of the multinational, prospective ORCHESTRA cohort. EclinMed. 2023;62:102107.","DOI":"10.1016\/j.eclinm.2023.102107"},{"key":"9570_CR5","doi-asserted-by":"publisher","first-page":"ofad277","DOI":"10.1093\/ofid\/ofad277","volume":"10","author":"M Gottlieb","year":"2023","unstructured":"Gottlieb M, Spatz ES, Yu H, Wisk LE, Elmore JG, Gentile NL, et al. Long COVID clinical phenotypes up to 6 months after infection identified by latent class analysis of self-reported symptoms. Open Forum Infect Dis. 2023;10:ofad277.","journal-title":"Open Forum Infect Dis"},{"key":"9570_CR6","doi-asserted-by":"crossref","unstructured":"Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM; Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400:452\u2013461.","DOI":"10.1016\/S0140-6736(22)01214-4"},{"key":"9570_CR7","doi-asserted-by":"crossref","unstructured":"de Bruijn S, Huiberts AJ, Andeweg SP, Hoeve CE, Schipper M, Grobbee DE, et al. Post-COVID-19 condition in individuals infected with SARS-CoV-2 in autumn 2023 in the Netherlands: a prospective cohort study with pre- and post-infection data. Lancet Reg Health. 2025;59:101472.","DOI":"10.1016\/j.lanepe.2025.101472"},{"key":"9570_CR8","unstructured":"Maatschappelijk Impact Team. Maatschappelijke gevolgen van long covid. 2023. https:\/\/open.overheid.nl\/documenten\/c7f4b621-f6a5-4cf4-bee3-ddf039caf2a9\/file. Accessed 3 Feb 2026."},{"key":"9570_CR9","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/s41577-023-00904-7","volume":"23","author":"DM Altmann","year":"2023","unstructured":"Altmann DM, Whettlock EM, Liu S, Arachchillage DJ, Boyton RJ. The immunology of long COVID. Nat Rev Immunol. 2023;23:618\u201334.","journal-title":"Nat Rev Immunol"},{"key":"9570_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1126\/science.adl0867","volume":"383","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly Z, Topol E. Solving the puzzle of long COVID. Science. 2024;383:830\u20132.","journal-title":"Science"},{"key":"9570_CR11","unstructured":"Federatie Medisch Specialisten. COVID-19 Richtlijn. 2022. https:\/\/richtlijnendatabase.nl\/richtlijn\/covid-19\/startpagina_-_covid-19.html. Accessed 3 Feb 2026."},{"key":"9570_CR12","unstructured":"Nederlands Huisartsengenootschap. NHG Standaard Langdurige Klachten na COVID-19 (M112). 2022. https:\/\/richtlijnen.nhg.org\/standaarden\/langdurige-klachten-na-covid-19. Accessed 3 Feb 2026."},{"key":"9570_CR13","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","volume":"18","author":"Adaptive Platform Trials Coalition","year":"2019","unstructured":"Adaptive Platform Trials Coalition. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18:797\u2013807.","journal-title":"Nat Rev Drug Discov"},{"key":"9570_CR14","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","volume":"27","author":"RD Hays","year":"2018","unstructured":"Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS\u00ae-29 v2.0 profile physical and mental health summary scores. Qual Life Res. 2018;27:1885\u201391.","journal-title":"Qual Life Res"},{"key":"9570_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0022-3999(94)90099-X","volume":"38","author":"JH Vercoulen","year":"1994","unstructured":"Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994;38:383\u201392.","journal-title":"J Psychosom Res"},{"key":"9570_CR16","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/1359105318805819","volume":"26","author":"LA Jason","year":"2021","unstructured":"Jason LA, Holtzman CS, Sunnquist M, Cotler J. The development of an instrument to assess post-exertional malaise in patients with myalgic encephalomyelitis and chronic fatigue syndrome. J Health Psychol. 2021;26:238\u201348.","journal-title":"J Health Psychol"},{"key":"9570_CR17","unstructured":"Heads of Medicines Agencies Clinical Trials Coordination Group. Recommendations related to contraception and pregnancy testing in clinical trials, version 1.2. 2024. https:\/\/www.hma.eu\/fileadmin\/dateien\/HMA_joint\/00-_About_HMA\/03-Working_Groups\/CTCG\/2024_HMA_CTCG_Contraception_guidance_Version_1.2__March_2024.pdf. Accessed 3 Feb 2026."},{"key":"9570_CR18","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","volume":"30","author":"CB Terwee","year":"2021","unstructured":"Terwee CB, Peipert JD, Chapman R, Lai JS, Terluin B, Cella D, et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021;30:2729\u201354.","journal-title":"Qual Life Res"},{"key":"9570_CR19","unstructured":"ICH Maintenance and Support Services Organization. MedDRA version 21.0. 2018. https:\/\/www.meddra.org\/. Accessed 3 Feb 2026."},{"key":"9570_CR20","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline for good clinical practice E6(R3). 2025. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf. Accessed 3 Feb 2026."},{"key":"9570_CR21","unstructured":"European Medicines Agency. EudraVigilance. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/pharmacovigilance-research-development\/eudravigilance. Accessed 3 Feb 2026."},{"key":"9570_CR22","unstructured":"International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated 2026. https:\/\/www.icmje.org\/recommendations\/. Accessed 3 Feb 2025."}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09570-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:03:44Z","timestamp":1774519424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09570-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9570"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09570-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial dossier was submitted for ethical approval via the European Clinical Trials Information System (EUCT number 2024-511580-28-02, trial documents available at URL:\n                      \n                      ) and was approved by the NedMec Medical Ethics Committee in the Netherlands (dossier number D-25-500086). Informed consent to participate is being obtained from all participants using a validated eConsenting system (Your Research, Amsterdam, Netherlands).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}